Development of a Topical 48-H Release Formulation as an Anti-scarring Treatment for Deep Partial-Thickness Burns

AAPS PharmSciTech. 2018 Jul;19(5):2264-2275. doi: 10.1208/s12249-018-1030-3. Epub 2018 May 11.

Abstract

The purpose of this study was to develop pirfenidone (PF) ointment formulations for a dose finding study in the prophylactic treatment of deep partial-thickness burns in a mouse model. A preformulation study was performed to evaluate the solubility of PF in buffers and different solvents and its stability. Three different formulations containing 1, 3.5, and 6.5% w/w PF were prepared and optimized for their composition for testing in mice. Optimized formulations showed promising in vitro release profiles, in which 20-45% of PF was released in the first 7 h and 70-90% released within 48 h. The rheological properties of the ointment remained stable throughout storage at 25 ± 2°C/60% RH. Animal studies showed treatments of burn wounds during the inflammatory stage of wound healing with PF ointments at different drug concentrations had no adverse effects on reepithelization. Moreover, 6.5% PF ointment (F3) reduced the expression of pro-inflammatory cytokines IL-12p70 and TNFα. This study suggests that hydrocarbon base ointment could be a promising dosage form for topical delivery of PF in treatment of deep partial-thickness burns.

Keywords: burn treatment; deep partial-thickness burn; mice; ointment formulations; pirfenidone.

MeSH terms

  • Administration, Topical
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Anti-Inflammatory Agents, Non-Steroidal / metabolism
  • Burns / drug therapy*
  • Burns / metabolism
  • Burns / pathology
  • Cicatrix / drug therapy*
  • Cicatrix / metabolism
  • Cicatrix / pathology
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / metabolism
  • Drug Liberation
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Ointments / administration & dosage
  • Ointments / metabolism
  • Pyridones / administration & dosage*
  • Pyridones / metabolism
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / metabolism
  • Wound Healing / drug effects
  • Wound Healing / physiology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Delayed-Action Preparations
  • Ointments
  • Pyridones
  • TNF protein, human
  • Tumor Necrosis Factor-alpha
  • pirfenidone